|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 21, 2018 ) In the year 2018, Global Non-Invasive Prenatal Testing Market was valued at USD 1.95 Billion. By the year 2023, it is predicted to reach USD 4.03 Billion with pace of 15.6% CAGR. There are different kinds of genetic tests for screening birth defects and inherited diseases. A simple blood sample is used to analyze DNA, which is also called as cell-free (cf-DNA) to determine a baby’s risk of different genetic disorder like Down syndrome. The gender of a fetus can also be found using NIPT. Non-Invasive Prenatal Testing is used to identify the most common chromosome anomalies such as, Patau Syndrome (Trisomy 13), Down syndrome (Trisomy 21), and Edwards Syndrome (Trisomy 18).
Request Report Sample: https://www.marketdataforecast.com/market-reports/non-Invasive-prenatal-testing-market-2818/request-sample
Growing risks of genetic disorders and growing interest for Non-Invasive techniques are estimated to drive the market.
Factors affecting market growth:
Factors like, the introduction of innovative and more advanced NIPT products. (+)
Feasibility and rising preference for non-invasive tests over invasive ones. (+)
Growing risk of chromosomal abnormalities in babies with growing maternal age and flexible reimbursement policies for NIPT. (+)
Major companies are playing a major role in expanding the boundaries of cf-DNA studies with attempts being at identifying about 20,000 genetic features through a single sample in a single reaction. (+)
Lower clinical validity of particularly the microdeletion segment is among the major restraints of the market. (-)
Get your customized report: https://www.marketdataforecast.com/market-reports/non-Invasive-prenatal-testing-market-2818/customize-report
North America leads the Global Non-Invasive Prenatal Testing Market.
Market Segmentation
Non-Invasive Prenatal Testing Market is segmented on the basis of geography
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
North America region is estimated to have highest share of global Non-Invasive Prenatal Testing Market. This is because of adaptation of high end technology and growing genetic abnormalities. United States is leading the region in terms of market share. Europe region is trailing right behind the North America region due to introduction of MIPT procedures into the market as well as growing awareness. It is estimated to have highest CAGR in forecasted period.
Browse full Table of Contents: https://www.marketdataforecast.com/market-reports/non-Invasive-prenatal-testing-market-2818/
Key players:
The major shareholders of the market include Beijing Genomics Institute (China), Agilent Technologies, Inc. (U.S.), QIAGEN N.V. (Germany), PerkinElmer, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), and GE Healthcare (U.S.).
Market Data Forecast.
Abhishek Shukla
+1-888-702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
